Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma
This Phase I study will test the safety and anti-myeloma activity of ascending doses of Descartes-08 (autologous CD8+ T-cells expressing an anti-BCMA chimeric antigen receptor) in eligible patients with active multiple myeloma.
Multiple Myeloma
BIOLOGICAL: Descartes-08|DRUG: Fludarabine|DRUG: Cyclophosphamide
Incidence (number) of Treatment-Emergent Adverse Events [Safety and Tolerability], Incidence (number) of Treatment-Emergent Adverse Events \[Safety and Tolerability\]. Descriptive statistics by incidence rate, body system classification, severity, and causality \[per protocol definitions\], 2 weeks
Treatment response, IMWG treatment response criteria, 1, 3, 6, 9 and 12 months
This Phase I study will test the safety and anti-myeloma activity of ascending doses of Descartes-08 (autologous CD8+ T-cells expressing an anti-BCMA chimeric antigen receptor) in eligible patients with active multiple myeloma.